NURL — Neural Therapeutics Balance Sheet
0.000.00%
- CA$1.33m
 - CA$1.08m
 
Annual balance sheet for Neural Therapeutics, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st  | 2023 July 31st  | 2024 July 31st  | |
|---|---|---|---|
| Period Length: | — | — | — | 
| Source: | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | 
| Cash | |||
| Cash and Short Term Investments | 0.372 | 0.273 | 0.067 | 
| Net Total Receivables | 0.051 | 0.069 | 0.028 | 
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 0.455 | 0.351 | 0.096 | 
| Total Assets | 0.455 | 0.351 | 0.096 | 
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 0.464 | 0.473 | 0.306 | 
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 0.464 | 0.613 | 0.78 | 
| Common Stock | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | -0.009 | -0.262 | -0.684 | 
| Total Liabilities & Shareholders' Equity | 0.455 | 0.351 | 0.096 | 
| Total Common Shares Outstanding |